請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76864完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林彥宏(Yen-Hung Lin) | |
| dc.contributor.author | Ya-Li Chen | en |
| dc.contributor.author | 陳雅麗 | zh_TW |
| dc.date.accessioned | 2021-07-10T21:38:56Z | - |
| dc.date.available | 2021-07-10T21:38:56Z | - |
| dc.date.copyright | 2020-09-10 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-17 | |
| dc.identifier.citation | References Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., . . . Participants of the German Conn's, R. (2009). Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab, 94(4), 1125-1130. doi:10.1210/jc.2008-2116 Catena, C., Colussi, G., Di Fabio, A., Valeri, M., Marzano, L., Uzzau, A., Sechi, L. A. (2010). Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res, 42(6), 440-445. doi:10.1055/s-0029-1246185 Catena, C., Colussi, G., Lapenna, R., Nadalini, E., Chiuch, A., Gianfagna, P., Sechi, L. A. (2007). Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension, 50(5), 911-918. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve db=PubMed dopt=Citation list_uids=17893375 Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., Sechi, L. A. (2008). Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment. Archives of Internal Medicine, 168(1), 80-85. doi:10.1001/archinternmed.2007.33 Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., Sechi, L. A. (2008). Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med, 168(1), 80-85. doi:10.1001/archinternmed.2007.33 Chang, Y. Y., Lee, H. H., Hung, C. S., Wu, X. M., Lee, J. K., Wang, S. M., . . . Group, T. S. (2014). Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clin Biochem, 47(13-14), 1329-1332. doi:10.1016/j.clinbiochem.2014.05.062 Chiang, C. E., Wu, T. J., Ueng, K. C., Chao, T. F., Chang, K. C., Wang, C. C., . . . Chen, S. A. (2016). 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc, 115(11), 893-952. doi:10.1016/j.jfma.2016.10.005 Chou, C. H., Hung, C. S., Liao, C. W., Wei, L. H., Chen, C. W., Shun, C. T., . . . Group, T. S. (2018). IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res, 114(5), 690-702. doi:10.1093/cvr/cvy013 Conn, J. W. (1955). Presidential address: Part I. Painting background Part II. Primary aldosteronism, a new clinical syndrome. The Journal of laboratory and clinical medicine, 45(1), 3-17. Deinum, J., Groenewoud, H., van der Wilt, G. J., Lenzini, L., Rossi, G. P. (2019). Adrenal venous sampling: cosyntropin stimulation or not? Eur J Endocrinol, 181(3), D15-d26. doi:10.1530/eje-18-0844 Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., . . . Young, W. F., Jr. (2016). The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 101(5), 1889-1916. doi:10.1210/jc.2015-4061 Hannemann, A., Wallaschofski, H. (2012). Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. Horm Metab Res, 44(3), 157-162. doi:10.1055/s-0031-1295438 Higgins, J. P. T., Thompson, S. G., Deeks, J. J., Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.), 327(7414), 557. doi:10.1136/bmj.327.7414.557 Huang, K. H., Yu, C. C., Hu, Y. H., Chang, C. C., Chan, C. K., Liao, S. C., . . . Taipai, T. P. A. I. (2019). Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 118(1 Pt 1), 72-82. doi:10.1016/j.jfma.2018.01.006 Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., Vaidya, A. (2018a). Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol, 3(8), 768-774. doi:10.1001/jamacardio.2018.2003 Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., Vaidya, A. (2018b). Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. Hypertension, 72(3), 658-666. doi:10.1161/hypertensionaha.118.11568 Hung, C. S., Chou, C. H., Liao, C. W., Lin, Y. T., Wu, X. M., Chang, Y. Y., . . . Group*, T. S. (2016). Aldosterone Induces Tissue Inhibitor of Metalloproteinases-1 Expression and Further Contributes to Collagen Accumulation: From Clinical to Bench Studies. Hypertension, 67(6), 1309-1320. doi:10.1161/HYPERTENSIONAHA.115.06768 Hung, C. S., Chou, C. H., Wu, X. M., Chang, Y. Y., Wu, V. C., Chen, Y. H., . . . Group, T. S. (2015). Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. J Hypertens, 33(9), 1922-1930; discussion 1930. doi:10.1097/HJH.0000000000000619 Katabami, T., Fukuda, H., Tsukiyama, H., Tanaka, Y., Takeda, Y., Kurihara, I., . . . Naruse, M. (2019). Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. J Hypertens, 37(7), 1513-1520. doi:10.1097/hjh.0000000000002070 Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., . . . Group, E. S. C. S. D. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37(38), 2893-2962. doi:10.1093/eurheartj/ehw210 Lavall, D., Selzer, C., Schuster, P., Lenski, M., Adam, O., Schäfers, H. J., . . . Laufs, U. (2014). The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem, 289(10), 6656-6668. doi:10.1074/jbc.M113.519256 Lenders, J. W. M., Eisenhofer, G., Reincke, M. (2017). Subtyping of Patients with Primary Aldosteronism: An Update. Horm Metab Res, 49(12), 922-928. doi:10.1055/s-0043-122602 Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., . . . Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed.), 339, b2700. doi:10.1136/bmj.b2700 Lin, Y. H., Wu, X. M., Lee, H. H., Lee, J. K., Liu, Y. C., Chang, H. W., . . . Group, T. S. (2012). Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens, 30(8), 1606-1613. doi:10.1097/HJH.0b013e3283550f93 Magill, S. B., Raff, H., Shaker, J. L., Brickner, R. C., Knechtges, T. E., Kehoe, M. E., Findling, J. W. (2001). Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab, 86(3), 1066-1071. doi:10.1210/jcem.86.3.7282 Manolis, A., Doumas, M. (2020). Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trio. J Hypertens, 38(2). Retrieved from https://journals.lww.com/jhypertension/Fulltext/2020/02000/Atrial_fibrillation,_arterial_hypertension,_and.7.aspx Mathur, A., Kemp, C. D., Dutta, U., Baid, S., Ayala, A., Chang, R. E., . . . Kebebew, E. (2010). Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg, 211(3), 384-390. doi:10.1016/j.jamcollsurg.2010.05.006 Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., Mourad, J.-J. (2005). Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology, 45(8), 1243-1248. doi:https://doi.org/10.1016/j.jacc.2005.01.015 Milliez, P., Girerd, X., Plouin, P. F., Blacher, J., Safar, M. E., Mourad, J. J. (2005). Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 45(8), 1243-1248. doi:10.1016/j.jacc.2005.01.015 Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., Mulatero, P. (2018). Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 6(1), 41-50. doi:10.1016/S2213-8587(17)30319-4 Mulatero, P., Monticone, S., Bertello, C., Viola, A., Tizzani, D., Iannaccone, A., . . . Veglio, F. (2013). Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab, 98(12), 4826-4833. doi:10.1210/jc.2013-2805 Pan, C. T., Chen, Z. W., Hung, C. S., Wu, V. C., Lin, Y. H. (2019). Different risk of new-onset atrial fibrillation on patients with primary aldosteronism after surgical or medical treatment: A nationwide longitudinal cohort-based study. Europace, 21, ii577-ii578. Retrieved from http://www.embase.com/search/results?subaction=viewrecord from=export id=L628292513 Reil, J. C., Hohl, M., Selejan, S., Lipp, P., Drautz, F., Kazakow, A., . . . Neuberger, H. R. (2012). Aldosterone promotes atrial fibrillation. Eur Heart J, 33(16), 2098-2108. doi:10.1093/eurheartj/ehr266 Rosenberg, M. A., Manning, W. J. (2012). Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation, 126(19), 2353-2362. doi:10.1161/CIRCULATIONAHA.112.113233 Rossi, G.-P., Sechi, L. A., Giacchetti, G., Ronconi, V., Strazzullo, P., Funder, J. W. (2008). Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends in Endocrinology Metabolism, 19(3), 88-90. Rossi, G. P., Cesari, M., Cuspidi, C., Maiolino, G., Cicala, M. V., Bisogni, V., . . . Pessina, A. C. (2013). Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension, 62(1), 62-69. doi:10.1161/HYPERTENSIONAHA.113.01316 Rossi, G. P., Maiolino, G., Flego, A., Belfiore, A., Bernini, G., Fabris, B., . . . Mantero, F. (2018). Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 71(4), 585-591. doi:10.1161/hypertensionaha.117.10596 Savard, S., Amar, L., Plouin, P.-F., Steichen, O. (2013). Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension, 62(2), 331-336. Seccia, T. M., Caroccia, B., Adler, G. K., Maiolino, G., Cesari, M., Rossi, G. P. (2017). Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. Hypertension, 69(4), 545-550. doi:10.1161/hypertensionaha.116.08956 Sterne, J. A. C., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., . . . Higgins, J. P. T. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed.), 355, i4919. doi:10.1136/bmj.i4919 Stowasser, M., Sharman, J., Leano, R., Gordon, R. D., Ward, G., Cowley, D., Marwick, T. H. (2005). Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I. The Journal of Clinical Endocrinology Metabolism, 90(9), 5070-5076. doi:10.1210/jc.2005-0681 Tsai, C. F., Yang, S. F., Chu, H. J., Ueng, K. C. (2013). Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol, 169(1), 17-28. doi:10.1016/j.ijcard.2013.06.046 Tsai, C. T., Chiang, F. T., Tseng, C. D., Hwang, J. J., Kuo, K. T., Wu, C. K., . . . Lin, J. L. (2010). Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol, 55(8), 758-770. doi:10.1016/j.jacc.2009.09.045 Velema, M., Dekkers, T., Hermus, A., Timmers, H., Lenders, J., Groenewoud, H., . . . Deinum, J. (2018). Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab, 103(1), 16-24. doi:10.1210/jc.2017-01442 Williams, T. A., Lenders, J. W. M., Mulatero, P., Burrello, J., Rottenkolber, M., Adolf, C., . . . Reincke, M. (2017). Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol, 5(9), 689-699. doi:10.1016/s2213-8587(17)30135-3 Wu, C. H., Yang, Y. W., Hung, S. C., Tsai, Y. C., Hu, Y. H., Lin, Y. H., . . . Wu, V. C. (2015). Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone. Sci Rep, 5, 15297. doi:10.1038/srep15297 Wu, V. C., Chang, C. H., Wang, C. Y., Lin, Y. H., Kao, T. W., Lin, P. C., . . . Chueh, S. J. (2017). Risk of Fracture in Primary Aldosteronism: A Population-Based Cohort Study. J Bone Miner Res, 32(4), 743-752. doi:10.1002/jbmr.3033 Wu, V. C., Chueh, S. C. J., Chen, L., Chang, C. H., Hu, Y. H., Lin, Y. H., . . . Yang, W. S. (2017). Risk of new-onset diabetes mellitus in primary aldosteronism: A population study over 5 years. Journal of Hypertension, 35(8), 1698-1708. doi:10.1097/HJH.0000000000001361 Wu, V. C., Hu, Y. H., Er, L. K., Yen, R. F., Chang, C. H., Chang, Y. L., . . . Wu, K. D. (2017). Case detection and diagnosis of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 116(12), 993-1005. doi:10.1016/j.jfma.2017.06.004 Wu, V. C., Hu, Y. H., Er, L. K., Yen, R. F., Chang, C. H., Chang, Y. L., . . . group, T. (2017). Case detection and diagnosis of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 116(12), 993-1005. doi:10.1016/j.jfma.2017.06.004 Young, W. F. (2007). Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 66(5), 607-618. doi:10.1111/j.1365-2265.2007.02775.x 14 PROTOCOL REFERENCES Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., . . . Participants of the German Conn's, R. (2009). Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab, 94(4), 1125-1130. doi:10.1210/jc.2008-2116 Catena, C., Colussi, G., Di Fabio, A., Valeri, M., Marzano, L., Uzzau, A., Sechi, L. A. (2010). Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res, 42(6), 440-445. doi:10.1055/s-0029-1246185 Catena, C., Colussi, G., Lapenna, R., Nadalini, E., Chiuch, A., Gianfagna, P., Sechi, L. A. (2007). Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension, 50(5), 911-918. doi:10.1161/HYPERTENSIONAHA.107.095448 Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., Sechi, L. A. (2008). Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med, 168(1), 80-85. doi:10.1001/archinternmed.2007.33 Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., Sechi, L. A. (2008). Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment. Archives of Internal Medicine, 168(1), 80-85. doi:10.1001/archinternmed.2007.33 Chang, Y. Y., Lee, H. H., Hung, C. S., Wu, X. M., Lee, J. K., Wang, S. M., . . . Group, T. S. (2014). Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clin Biochem, 47(13-14), 1329-1332. doi:10.1016/j.clinbiochem.2014.05.062 Chiang, C. E., Wu, T. J., Ueng, K. C., Chao, T. F., Chang, K. C., Wang, C. C., . . . Chen, S. A. (2016). 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc, 115(11), 893-952. doi:10.1016/j.jfma.2016.10.005 Chou, C. H., Hung, C. S., Liao, C. W., Wei, L. H., Chen, C. W., Shun, C. T., . . . Group, T. S. (2018). IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res, 114(5), 690-702. doi:10.1093/cvr/cvy013 Conn, J. W. (1955). Presidential address: Part I. Painting background Part II. Primary aldosteronism, a new clinical syndrome. The Journal of laboratory and clinical medicine, 45(1), 3-17. Deinum, J., Groenewoud, H., van der Wilt, G. J., Lenzini, L., Rossi, G. P. (2019). Adrenal venous sampling: cosyntropin stimulation or not? Eur J Endocrinol, 181(3), D15-d26. doi:10.1530/eje-18-0844 Deinum, J., Riksen, N. P., Lenders, J. W. M. (2015). Pharmacological treatment of aldosterone excess. Pharmacology Therapeutics, 154, 120-133. doi:https://doi.org/10.1016/j.pharmthera.2015.07.006 Fu, B., Zhang, X., Wang, G. X., Lang, B., Ma, X., Li, H. Z., . . . Zheng, T. (2011). Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol, 185(5), 1578-1582. doi:10.1016/j.juro.2010.12.051 Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., . . . Young, W. F., Jr. (2016). The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 101(5), 1889-1916. doi:10.1210/jc.2015-4061 Gomez-Sanchez, E. P. (2016). Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth? J Cardiovasc Pharmacol, 67(1), 26-38. doi:10.1097/fjc.0000000000000329 Hannemann, A., Wallaschofski, H. (2012). Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. Horm Metab Res, 44(3), 157-162. doi:10.1055/s-0031-1295438 Higgins, J. P. T., Thompson, S. G., Deeks, J. J., Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.), 327(7414), 557. doi:10.1136/bmj.327.7414.557 Huang, K. H., Yu, C. C., Hu, Y. H., Chang, C. C., Chan, C. K., Liao, S. C., . . . Lin, Y. H. (2019). Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 118(1 Pt 1), 72-82. doi:10.1016/j.jfma.2018.01.006 Huang, K. H., Yu, C. C., Hu, Y. H., Chang, C. C., Chan, C. K., Liao, S. C., . . . Taipai, T. P. A. I. (2019). Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 118(1 Pt 1), 72-82. doi:10.1016/j.jfma.2018.01.006 Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., Vaidya, A. (2018a). Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol, 3(8), 768-774. doi:10.1001/jamacardio.2018.2003 Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., Vaidya, A. (2018b). Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. Hypertension, 72(3), 658-666. doi:10.1161/hypertensionaha.118.11568 Hung, C. S., Chou, C. H., Liao, C. W., Lin, Y. T., Wu, X. M., Chang, Y. Y., . . . Group*, T. S. (2016). Aldosterone Induces Tissue Inhibitor of Metalloproteinases-1 Expression and Further Contributes to Collagen Accumulation: From Clinical to Bench Studies. Hypertension, 67(6), 1309-1320. doi:10.1161/HYPERTENSIONAHA.115.06768 Hung, C. S., Chou, C. H., Wu, X. M., Chang, Y. Y., Wu, V. C., Chen, Y. H., . . . Group, T. S. (2015). Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. J Hypertens, 33(9), 1922-1930; discussion 1930. doi:10.1097/HJH.0000000000000619 Katabami, T., Fukuda, H., Tsukiyama, H., Tanaka, Y., Takeda, Y., Kurihara, I., . . . Naruse, M. (2019). Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. J Hypertens, 37(7), 1513-1520. doi:10.1097/hjh.0000000000002070 Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., . . . Group, E. S. C. S. D. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 37(38), 2893-2962. doi:10.1093/eurheartj/ehw210 Lavall, D., Selzer, C., Schuster, P., Lenski, M., Adam, O., Schäfers, H. J., . . . Laufs, U. (2014). The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem, 289(10), 6656-6668. doi:10.1074/jbc.M113.519256 Lenders, J. W. M., Eisenhofer, G., Reincke, M. (2017). Subtyping of Patients with Primary Aldosteronism: An Update. Horm Metab Res, 49(12), 922-928. doi:10.1055/s-0043-122602 Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., . . . Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed.), 339, b2700. doi:10.1136/bmj.b2700 Lin, Y. H., Wu, X. M., Lee, H. H., Lee, J. K., Liu, Y. C., Chang, H. W., . . . Group, T. S. (2012). Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens, 30(8), 1606-1613. doi:10.1097/HJH.0b013e3283550f93 Magill, S. B., Raff, H., Shaker, J. L., Brickner, R. C., Knechtges, T. E., Kehoe, M. E., Findling, J. W. (2001). Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab, 86(3), 1066-1071. doi:10.1210/jcem.86.3.7282 Manolis, A., Doumas, M. (2020). Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trio. J Hypertens, 38(2). Retrieved from https://journals.lww.com/jhypertension/Fulltext/2020/02000/Atrial_fibrillation,_arterial_hypertension,_and.7.aspx Mathur, A., Kemp, C. D., Dutta, U., Baid, S., Ayala, A., Chang, R. E., . . . Kebebew, E. (2010). Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg, 211(3), 384-390. doi:10.1016/j.jamcollsurg.2010.05.006 Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., Mourad, J.-J. (2005). Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology, 45(8), 1243-1248. doi:https://doi.org/10.1016/j.jacc.2005.01.015 Milliez, P., Girerd, X., Plouin, P. F., Blacher, J., Safar, M. E., Mourad, J. J. (2005). Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 45(8), 1243-1248. doi:10.1016/j.jacc.2005.01.015 Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., Mulatero, P. (2018). Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 6(1), 41-50. doi:10.1016/S2213-8587(17)30319-4 Mulatero, P., Monticone, S., Bertello, C., Viola, A., Tizzani, D., Iannaccone, A., . . . Veglio, F. (2013). Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab, 98(12), 4826-4833. doi:10.1210/jc.2013-2805 Pan, C. T., Chen, Z. W., Hung, C. S., Wu, V. C., Lin, Y. H. (2019). Different risk of new-onset atrial fibrillation on patients with primary aldosteronism after surgical or medical treatment: A nationwide longitudinal cohort-based study. Europace, 21, ii577-ii578. Retrieved from http://www.embase.com/search/results?subaction=viewrecord from=export id=L628292513 Reil, J. C., Hohl, M., Selejan, S., Lipp, P., Drautz, F., Kazakow, A., . . . Neuberger, H. R. (2012). Aldosterone promotes atrial fibrillation. Eur Heart J, 33(16), 2098-2108. doi:10.1093/eurheartj/ehr266 Rosenberg, M. A., Manning, W. J. (2012). Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation, 126(19), 2353-2362. doi:10.1161/CIRCULATIONAHA.112.113233 Rossi, G.-P., Sechi, L. A., Giacchetti, G., Ronconi, V., Strazzullo, P., Funder, J. W. (2008). Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends in Endocrinology Metabolism, 19(3), 88-90. Rossi, G. P., Cesari, M., Cuspidi, C., Maiolino, G., Cicala, M. V., Bisogni, V., . . . Pessina, A. C. (2013). Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension, 62(1), 62-69. doi:10.1161/HYPERTENSIONAHA.113.01316 Rossi, G. P., Maiolino, G., Flego, A., Belfiore, A., Bernini, G., Fabris, B., . . . Mantero, F. (2018). Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 71(4), 585-591. doi:10.1161/hypertensionaha.117.10596 Savard, S., Amar, L., Plouin, P.-F., Steichen, O. (2013). Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension, 62(2), 331-336. Seccia, T. M., Caroccia, B., Adler, G. K., Maiolino, G., Cesari, M., Rossi, G. P. (2017). Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. Hypertension, 69(4), 545-550. doi:10.1161/hypertensionaha.116.08956 Shigematsu, K., Kawai, K., Irie, J., Sakai, H., Nakashima, O., Iguchi, A., . . . Takahara, O. (2006). Analysis of unilateral adrenal hyperplasia with primary aldosteronism from the aspect of messenger ribonucleic acid expression for steroidogenic enzymes: a comparative study with adrenal cortices adhering to aldosterone-producing adenoma. Endocrinology, 147(2), 999-1006. doi:10.1210/en.2005-0765 Sica, D. A. (2005). Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart failure reviews, 10(1), 23-29. Sterne, J. A. C., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., . . . Higgins, J. P. T. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed.), 355, i4919. doi:10.1136/bmj.i4919 Stowasser, M., Sharman, J., Leano, R., Gordon, R. D., Ward, G., Cowley, D., Marwick, T. H. (2005). Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I. The Journal of Clinical Endocrinology Metabolism, 90(9), 5070-5076. doi:10.1210/jc.2005-0681 Tsai, C. F., Yang, S. F., Chu, H. J., Ueng, K. C. (2013). Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol, 169(1), 17-28. doi:10.1016/j.ijcard.2013.06.046 Tsai, C. T., Chiang, F. T., Tseng, C. D., Hwang, J. J., Kuo, K. T., Wu, C. K., . . . Lin, J. L. (2010). Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol, 55(8), 758-770. doi:10.1016/j.jacc.2009.09.045 Velema, M., Dekkers, T., Hermus, A., Timmers, H., Lenders, J., Groenewoud, H., . . . Deinum, J. (2018). Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab, 103(1), 16-24. doi:10.1210/jc.2017-01442 Williams, T. A., Lenders, J. W. M., Mulatero, P., Burrello, J., Rottenkolber, M., Adolf, C., . . . Reincke, M. (2017). Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol, 5(9), 689-699. doi:10.1016/s2213-8587(17)30135-3 Wu, C. H., Yang, Y. W., Hung, S. C., Tsai, Y. C., Hu, Y. H., Lin, Y. H., . . . Wu, V. C. (2015). Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone. Sci Rep, 5, 15297. doi:10.1038/srep15297 Wu, V. C., Chang, C. H., Wang, C. Y., Lin, Y. H., Kao, T. W., Lin, P. C., . . . Chueh, S. J. (2017). Risk of Fracture in Primary Aldosteronism: A Population-Based Cohort Study. J Bone Miner Res, 32(4), 743-752. doi:10.1002/jbmr.3033 Wu, V. C., Chueh, S. C. J., Chen, L., Chang, C. H., Hu, Y. H., Lin, Y. H., . . . Yang, W. S. (2017). Risk of new-onset diabetes mellitus in primary aldosteronism: A population study over 5 years. Journal of Hypertension, 35(8), 1698-1708. doi:10.1097/HJH.0000000000001361 Wu, V. C., Hu, Y. H., Er, L. K., Yen, R. F., Chang, C. H., Chang, Y. L., . . . Wu, K. D. (2017). Case detection and diagnosis of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 116(12), 993-1005. doi:10.1016/j.jfma.2017.06.004 Wu, V. C., Hu, Y. H., Er, L. K., Yen, R. F., Chang, C. H., Chang, Y. L., . . . group, T. (2017). Case detection and diagnosis of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc, 116(12), 993-1005. doi:10.1016/j.jfma.2017.06.004 Wu, V. C., Wang, S. M., Chang, C. H., Hu, Y. H., Lin, L. Y., Lin, Y. H., . . . Wu, K. D. (2016). Long term outcome of Aldosteronism after target treatments. Sci Rep, 6, 32103. doi:10.1038/srep32103 Young, W. F. (2007). Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf), 66(5), 607-618. doi:10.1111/j.1365-2265.2007.02775.x | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76864 | - |
| dc.description.abstract | 背景 原發性皮質醛酮症患者有較高的心房顫動的罹病率和其他心血管併發症。然而，對於經腎上腺切除手術或口服藥物(醛固酮受體阻斷劑)治療後，預防新生心房顫動的效果尚不清楚。這項統合分析研究的目的是評估原發性皮質醛酮症患者接受醛固酮受體阻斷劑口服藥物治療或是腎上腺切除術發生新生心房顫動的差異。 方法 在PubMed，Embase和Cochrane資料庫進行隨機分派或觀察性研究的文獻搜尋，研究調查原發性皮質醛酮症患者接受藥物治療後或手術治療後的新生心房顫動發生率。將原發性皮質醛酮症患者接受手術治療、藥物治療及一般高血壓患者的新生心房顫動發生率進行統合分析。納入研究的偏倚風險使用非隨機干預研究的偏倚風險（ROBINS-I）評估表。 結果 統合分析共檢索了37篇相關文章，其中3篇符合納入標準的研究（共2705名PA患者）被納入研究，審查過程根據PRISMA指南進行。薈萃分析結果發現，原發性皮質醛酮症患者接受醛固酮受體阻斷劑治療比手術治療，其新生心房顫動的發生率較高（固定效應模型的勝算比: 2.99, 95%信賴區間: 1.86-4.82, p < 0.001）。異質性分析（I2 = 0）其趨近同質性。經漏斗圖和Egger回歸不對稱檢驗評估，無出版性的偏誤(p = 0.91)。接受藥物治療的原發性皮質醛酮症患者與原發性高血壓患者相較下，其新生心房顫動的發生率較高（隨機效應模型的勝算比: 1.91, 95% 信賴區間: 1.11-3.29）；接受手術治療的原發性皮質醛酮症患者發生新生心房顫動的風險與原發性高血壓患者相較下，是沒有顯著相關（隨機效應模型的勝算比: 0.71, 95%信賴區間: 0.27-1.85）。 結論 原發性皮質醛酮症患者接受醛固酮受體阻斷劑治療相較於原發性皮質醛酮症患者接受手術治療或原發性高血壓患者，其新生心房顫動的發生率較高。 | zh_TW |
| dc.description.abstract | Background Primary aldosteronism (PA) is associated with a higher prevalence of atrial fibrillation and other cardiovascular complications. However, the effect of targeted treatment to prevent new-onset atrial fibrillation (NOAF) remains unclear. The aim of this meta-analysis study was to assess the risk of NOAF among PA patients receiving mineralocorticoid receptor antagonist (MRA) treatment, PA patients receiving adrenalectomy, and patients with essential hypertension (EH). Methods Randomized or observational studies that investigated the incidence rate of NOAF in PA patients receiving MRA treatment versus PA patients receiving adrenalectomy were identified in searches of PubMed, Embase and Cochrane Library. Meta-analyses of NOAF events in PA patients receiving MRA treatment, PA patients receiving adrenalectomy, and patients with EH were conducted. Results A total of 37 related studies were reviewed, of which 3 fulfilled the inclusion criteria, including a total of 2,705 PA patients. The results of meta-analysis demonstrated a higher incidence of NOAF among the PA patients receiving MRA treatment compared to the PA patients receiving adrenalectomy (odds ratio [OR]: 2.99, 95% confidence interval [CI]: 1.86-4.82, p < 0.001 in a fixed effects model). The pooled OR for the PA patients receiving MRA treatment compared to the patients with EH was 1.91 (95% CI: 1.11-3.29). The pooled OR for the PA patients receiving adrenalectomy compared to the patients with EH was 0.71 (95% CI: 0.27-1.85). Conclusion Compared to the EH patients and the PA patients receiving adrenalectomy, the patients with PA receiving MRA treatment had a higher risk of NOAF. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-10T21:38:56Z (GMT). No. of bitstreams: 1 U0001-1208202023311400.pdf: 1486971 bytes, checksum: 5cb26f60af592aec328283919edd642f (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 目錄 口試委員會審定書 i 誠摯感謝 ii 中文摘要 iii Abstract v 1. Introduction 1 2. Material and method 4 2.1 Search strategy and selection criteria 4 2.2 Data extraction and quality assessment 5 2.3 Outcomes of interest 5 2.4 Statistical analysis 5 3. Results 7 3.1 Included studies 7 3.2 Quality assessment 7 3.3 NOAF events 7 4. Discussion 9 4.1 Main findings and discussion 9 4.2 Limitations 12 5. Conclusions 14 References 15 Attachment: Protocol 27 SYNOPSIS 28 1 FLOW CHARTS 35 1.1 Graphical study design 35 1.2 Study flow chart 36 2 TABLE OF CONTENTS 39 3 LIST OF ABBREVIATIONS 42 4 INTRODUCTION AND RATIONALE 44 4.1 Background: disease 44 4.2 Background: adrenalectomy and spironolactone 45 4.3 Rationale for the study design 47 5 STUDY OBJECTIVES 49 5.1 Primary objective 49 5.2 Secondary objectives 49 5.3 Others 49 6 STUDY DESIGN 50 6.1 Description of the study 50 6.2 Screening period 50 6.3 Randomization open-label Treatment period / Observation period 51 6.3.1 Randomization open-label Treatment period 51 6.3.2 Randomization open-label Observation period 52 6.4 End of the study 52 7 SELECTION OF SUBJECTS 53 7.1 Inclusion criteria 53 7.2 Exclusion criteria 53 8 STUDY TREATMENTS 55 8.1 Investigational medicinal product 55 8.1.1 Dose up-titration and adjustment 55 8.2 Treatment assignment, randomization 56 8.3 Storage conditions and shelf life 57 9 ASSESSMENT OF INVESTIGATIONAL ENDPOINTS 58 9.1 Endpoint 58 9.1.1 Primary endpoint 58 9.1.2 Secondary endpoints 58 9.1.3 Other endpoints 58 9.2 Safety endpoints 58 10 STUDY PROCEDURES 59 10.1 Visit schedule 59 10.1.1 Screening period 59 10.1.2 Randomized open-label Treatment/Observation period 61 10.2 Subject withdrawal/early termination 68 10.2.1 Withdrawal of consent 68 10.2.2 Lost to follow-up 68 10.3 Adverse event reporting and safety monitoring 68 10.3.1 Adverse events 68 10.3.2 Serious adverse events 69 10.3.3 Unexpected adverse event 69 11 STATISTICAL CONSIDERATIONS 71 11.1 Determination of sample size 71 11.2 Disposition of subjects 71 11.3 Analysis population 71 11.3.1 Efficacy populations 72 11.3.2 Safety population 72 11.4 Statistical methods 72 11.4.1 Extent of study treatment exposure and compliance 72 11.4.2 Analyses of endpoints 73 11.4.3 Analyses of efficacy safety data 74 12 ETHICAL AND REGULATORY CONSIDERATIONS 79 12.1 Ethical and regulatory standards 79 12.2 Informed consent 79 12.3 Health authorities and institutional review board independent ethics committee 79 13 STUDY MONITORING 81 13.1 Responsibilities of the Investigator(s) 81 13.2 Source document requirements 81 13.3 Use and completion of case report forms (CRFs) and additional requests 82 13.4 Use of computerized systems 82 14 PROTOCOL REFERENCES 84 圖目錄 Figure 1 Flow chart of the literature search 20 Figure 2 Forest plots of NOAF in PA patients receiving MRA treatment vs adrenalectomy 21 Figure 3 Funnel plot of NOAF in PA patients receiving MRA treatment vs adrenalectomy 22 Figure 4 Forest plot of NOAF in PA patients receiving MRA treatment vs EH patients 23 Figure 5 Forest plot of NOAF in PA patients receiving adrenalectomy vs EH patients 24 表目錄 Table 1 25 Table 2 26 | |
| dc.language.iso | zh-TW | |
| dc.title | 原發性皮質醛酮症患者接受腎上腺切除術或醛固酮受體阻斷劑治療後產生新生心房顫動的差異之統合分析 | zh_TW |
| dc.title | New-onset atrial fibrillation in patients with primary aldosteronism receiving either adrenalectomy or mineralocorticoid receptor antagonist treatment: A meta-analysis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林家齊(Chia-Chi Lin),吳允升(Vin-Cent Wu) | |
| dc.subject.keyword | 醛固酮增多症,原發性醛固酮增多症,腎上腺切除術,醛固酮受體阻斷劑,心房顫動, | zh_TW |
| dc.subject.keyword | hyperaldosteronism,primary aldosteronism,adrenalectomy,mineralocorticoid receptor antagonist,atrial fibrillation, | en |
| dc.relation.page | 88 | |
| dc.identifier.doi | 10.6342/NTU202003172 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2020-08-17 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1208202023311400.pdf 目前未授權公開取用 | 1.45 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。